TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Marker Therapeutics ( (MRKR) ) is now available.
Marker Therapeutics reported promising results from its APOLLO study, showing a 66% objective response rate and a 50% complete response rate in relapsed Non-Hodgkin lymphoma patients treated with MT-601. The company also treated the first patient in its Off-the-Shelf program for Acute Myeloid Leukemia and Myelodysplastic Syndrome, and entered a manufacturing collaboration with Cellipont Bioservices to scale up production, strengthening its operational and financial position.
The most recent analyst rating on (MRKR) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Marker Therapeutics stock, see the MRKR Stock Forecast page.
Spark’s Take on MRKR Stock
According to Spark, TipRanks’ AI Analyst, MRKR is a Neutral.
Marker Therapeutics is positioned in the biotechnology industry, characterized by high potential but also significant risks. The company exhibits strong revenue growth but faces challenges with profitability and cash flow. Technical indicators present a mixed outlook, with some potential for price reversals. The valuation reflects typical industry dynamics, favoring growth over profitability. Investors should be cautious, focusing on the company’s ability to manage cash flow and improve operational efficiencies to support future growth.
To see Spark’s full report on MRKR stock, click here.
More about Marker Therapeutics
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based therapies. The company primarily targets relapsed or refractory B-cell lymphoma and other cancers, with a market focus on innovative cancer treatments.
Average Trading Volume: 1,004,027
Technical Sentiment Signal: Strong Sell
Current Market Cap: $12.21M
See more data about MRKR stock on TipRanks’ Stock Analysis page.